Yunchao Huang

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Medicine, Oncology, Pharmacology +11

YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression

Yulin Shi, Songqing Fan, Mengge Wu et al. · Nature Communications · 2019 · 375 citations · Full text

Medicine, Molecular Biology, Oncology +17

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou et al. · Annals of Oncology · 2016 · 188 citations

Pharmacy, Oncology, Pharmacology +17

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He, Chunxia Su, Wenhua Liang et al. · The Lancet Respiratory Medicine · 2021 · 184 citations

Medicine, Oncology, Pharmacology +13

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17